Overview
Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer.
Last reviewed: 24 May 2023
Diagnostics guidance 53 has been migrated to HealthTech guidance 678.
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.